Dysmenorrhea

(redirected from dysmenorrhoea)
Also found in: Dictionary, Thesaurus, Medical.

dysmenorrhea

[dis‚men·ə′rē·ə]
(medicine)
Difficult or painful menstruation.

Dysmenorrhea

 

disturbances of menstruation, characterized by pains in the lower abdomen, the small of the back, and the sacrum (algomenorrhea), combined with general symptoms (migraine, heart palpitations, vomiting, diarrhea, skin rashes, and sleep disturbance).

Primary dysmenorrhea occurs in women with no previous gynecological disease, most often in young girls and young women who have not given birth. This dysmenorrhea often ceases with a regular sex life and especially after parturition. Secondary dysmenorrhea appears as a result of inflammatory processes, the development of tumors in the woman’s sex organs, version of the uterus, and so on. Dysmenorrhea may develop as a result of psychological shock associated with the onset of the first menstruation in uninformed young girls, when there is a long-unfulfilled desire to become pregnant, and in cases of unsatisfactory sex life. Sometimes dysmenorrhea arises owing to the functional characteristics of a woman’s nervous system (vagotonic form). A special form of dysmenorrhea is membranous dysmenorrhea, which is associated with hormonal disharmony (the preponderance of estrogen over the hormone of the corpus luteum).

Treatment depends on the causes of the dysmenorrhea and its form. General restorative treatment, pain relievers, sedatives, hormone therapy, and physical therapy are prescribed.

References in periodicals archive ?
Table 1: Coxibs currently on the market Generic Name Originator Any Indication etoricoxib Merck & Co Arthritis, osteo Arthritis, rheumatoid Pain, musculoskeletal Pain, post-operative Dysmenorrhoea celecoxib Pfizer Arthritis, rheumatoid Arthritis, osteo Pain, musculoskeletal valdecoxib Pfizer Arthritis, rheumatoid Arthritis, osteo Pain, musculoskeletal Dysmenorrhoea parecoxib sodium Pfizer Pain, post-operative
Current treatments for dysmenorrhoea include over-the-counter (OTC) painkillers such as the NSAIDs naproxen and ibuprofen.
Vantia Therapeutics, a company focusing on first-in-class therapies for unmet medical needs, announces further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea.
The trial will recruit 128 women aged between 18 and 35 years with primary dysmenorrhoea including a consistent history of menstrual pain that limits daily activity and typically requires medication for relief.
There's no question that a low dose of a combined oral contraceptive will help some women with dysmenorrhoea.
VA111913 is a small molecule oral drug candidate, discovered by Vantia Therapeutics, and in clinical development for the treatment of dysmenorrhoea, a condition characterised by abnormal contractions of the uterus during menstruation causing severe, and often debilitating pain.
Its rapidly advancing clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, product candidates which directly target the causes of conditions that together affect many millions of people, are poorly treated and represent billion dollar markets.
In women with bad dysmenorrhoea, the uterus is hypersensitive and contracts more violently and frequently.
Diagnosis and management of dysmenorrhoea BMJ 2006;332:1134-1138.
We found there was a significant difference in the severity of dysmenorrhoea depending on whether or not the women used combined oral contraceptives.
Primary dysmenorrhoea usually begins within a year or 2 of your first period.